Vaccine Effectiveness against Mpox in the United States
To the Editor: Deputy et al. (June 29 issue) 1 report the estimated vaccine effectiveness of JYNNEOS vaccination against mpox in a case–control study. Their estimate of vaccine effectiveness with a single dose is substantially lower than the estimates from previous reports. The definition of the con...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2023-10, Vol.389 (15), p.1440-1441 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1441 |
|---|---|
| container_issue | 15 |
| container_start_page | 1440 |
| container_title | The New England journal of medicine |
| container_volume | 389 |
| creator | Arbel, Ronen Zucker, Roy Wolff-Sagy, Yael Deputy, Nicholas P. Gerhart, Jacqueline L. Feldstein, Leora R. |
| description | To the Editor:
Deputy et al. (June 29 issue)
1
report the estimated vaccine effectiveness of JYNNEOS vaccination against mpox in a case–control study. Their estimate of vaccine effectiveness with a single dose is substantially lower than the estimates from previous reports. The definition of the control group (patients with an incident diagnosis of human immunodeficiency virus [HIV] infection or a new or refill order for preexposure prophylaxis against HIV infection) may not be representative of the patients who are intended to receive the vaccine against mpox. Indeed, only 309 of 2266 patients with mpox (13.6%) met these criteria. Moreover, the . . . |
| doi_str_mv | 10.1056/NEJMc2309583 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2876636898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2876058167</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-c171855bb8926a8b3ab20b1cf912533b69311d7f52a4929d0ab38cd085243e943</originalsourceid><addsrcrecordid>eNpt0DtPwzAUBWALgWgpbMwoEgwMBPyOPaKqvNTCAGWNbOcGUjVOiV0E_55AC0KIu9zl09HRQWif4FOChTy7Hd1MHGVYC8U2UJ8IxlLOsdxEfYypSnmmWQ_thDDD3RGut1GPZYpoLWUfZY_GucpDMipLcLF6BQ8hJObJVD7EZLJo3pLKJ_EZkqmvIhTJfTQRwi7aKs08wN76D9D0YvQwvErHd5fXw_Nx6hhXMXUkI0oIa5Wm0ijLjKXYEldqQruiVmpGSJGVghquqS6wsUy5AitBOQPN2QAdr3IXbfOyhBDzugoO5nPjoVmGnKpMSiaVVh09_ENnzbL1XbsvhYUiMuvUyUq5tgmhhTJftFVt2vec4Pxz0Pz3oB0_WIcubQ3FD_5esANHK1DXIfcwq__P-QB9GHhi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2876058167</pqid></control><display><type>article</type><title>Vaccine Effectiveness against Mpox in the United States</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Arbel, Ronen ; Zucker, Roy ; Wolff-Sagy, Yael ; Deputy, Nicholas P. ; Gerhart, Jacqueline L. ; Feldstein, Leora R.</creator><creatorcontrib>Arbel, Ronen ; Zucker, Roy ; Wolff-Sagy, Yael ; Deputy, Nicholas P. ; Gerhart, Jacqueline L. ; Feldstein, Leora R.</creatorcontrib><description>To the Editor:
Deputy et al. (June 29 issue)
1
report the estimated vaccine effectiveness of JYNNEOS vaccination against mpox in a case–control study. Their estimate of vaccine effectiveness with a single dose is substantially lower than the estimates from previous reports. The definition of the control group (patients with an incident diagnosis of human immunodeficiency virus [HIV] infection or a new or refill order for preexposure prophylaxis against HIV infection) may not be representative of the patients who are intended to receive the vaccine against mpox. Indeed, only 309 of 2266 patients with mpox (13.6%) met these criteria. Moreover, the . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc2309583</identifier><identifier>PMID: 37819966</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Conflicts of interest ; Disease control ; Disease prevention ; Effectiveness studies ; Estimates ; HIV ; Human immunodeficiency virus ; Humans ; Immunization ; Infections ; Mpox ; Mpox (monkeypox) ; Prophylaxis ; United States ; Vaccine Efficacy ; Vaccines</subject><ispartof>The New England journal of medicine, 2023-10, Vol.389 (15), p.1440-1441</ispartof><rights>Copyright © 2023 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-c171855bb8926a8b3ab20b1cf912533b69311d7f52a4929d0ab38cd085243e943</citedby><cites>FETCH-LOGICAL-c348t-c171855bb8926a8b3ab20b1cf912533b69311d7f52a4929d0ab38cd085243e943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc2309583$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMc2309583$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37819966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arbel, Ronen</creatorcontrib><creatorcontrib>Zucker, Roy</creatorcontrib><creatorcontrib>Wolff-Sagy, Yael</creatorcontrib><creatorcontrib>Deputy, Nicholas P.</creatorcontrib><creatorcontrib>Gerhart, Jacqueline L.</creatorcontrib><creatorcontrib>Feldstein, Leora R.</creatorcontrib><title>Vaccine Effectiveness against Mpox in the United States</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Deputy et al. (June 29 issue)
1
report the estimated vaccine effectiveness of JYNNEOS vaccination against mpox in a case–control study. Their estimate of vaccine effectiveness with a single dose is substantially lower than the estimates from previous reports. The definition of the control group (patients with an incident diagnosis of human immunodeficiency virus [HIV] infection or a new or refill order for preexposure prophylaxis against HIV infection) may not be representative of the patients who are intended to receive the vaccine against mpox. Indeed, only 309 of 2266 patients with mpox (13.6%) met these criteria. Moreover, the . . .</description><subject>Conflicts of interest</subject><subject>Disease control</subject><subject>Disease prevention</subject><subject>Effectiveness studies</subject><subject>Estimates</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infections</subject><subject>Mpox</subject><subject>Mpox (monkeypox)</subject><subject>Prophylaxis</subject><subject>United States</subject><subject>Vaccine Efficacy</subject><subject>Vaccines</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0DtPwzAUBWALgWgpbMwoEgwMBPyOPaKqvNTCAGWNbOcGUjVOiV0E_55AC0KIu9zl09HRQWif4FOChTy7Hd1MHGVYC8U2UJ8IxlLOsdxEfYypSnmmWQ_thDDD3RGut1GPZYpoLWUfZY_GucpDMipLcLF6BQ8hJObJVD7EZLJo3pLKJ_EZkqmvIhTJfTQRwi7aKs08wN76D9D0YvQwvErHd5fXw_Nx6hhXMXUkI0oIa5Wm0ijLjKXYEldqQruiVmpGSJGVghquqS6wsUy5AitBOQPN2QAdr3IXbfOyhBDzugoO5nPjoVmGnKpMSiaVVh09_ENnzbL1XbsvhYUiMuvUyUq5tgmhhTJftFVt2vec4Pxz0Pz3oB0_WIcubQ3FD_5esANHK1DXIfcwq__P-QB9GHhi</recordid><startdate>20231012</startdate><enddate>20231012</enddate><creator>Arbel, Ronen</creator><creator>Zucker, Roy</creator><creator>Wolff-Sagy, Yael</creator><creator>Deputy, Nicholas P.</creator><creator>Gerhart, Jacqueline L.</creator><creator>Feldstein, Leora R.</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20231012</creationdate><title>Vaccine Effectiveness against Mpox in the United States</title><author>Arbel, Ronen ; Zucker, Roy ; Wolff-Sagy, Yael ; Deputy, Nicholas P. ; Gerhart, Jacqueline L. ; Feldstein, Leora R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-c171855bb8926a8b3ab20b1cf912533b69311d7f52a4929d0ab38cd085243e943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Conflicts of interest</topic><topic>Disease control</topic><topic>Disease prevention</topic><topic>Effectiveness studies</topic><topic>Estimates</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infections</topic><topic>Mpox</topic><topic>Mpox (monkeypox)</topic><topic>Prophylaxis</topic><topic>United States</topic><topic>Vaccine Efficacy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arbel, Ronen</creatorcontrib><creatorcontrib>Zucker, Roy</creatorcontrib><creatorcontrib>Wolff-Sagy, Yael</creatorcontrib><creatorcontrib>Deputy, Nicholas P.</creatorcontrib><creatorcontrib>Gerhart, Jacqueline L.</creatorcontrib><creatorcontrib>Feldstein, Leora R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arbel, Ronen</au><au>Zucker, Roy</au><au>Wolff-Sagy, Yael</au><au>Deputy, Nicholas P.</au><au>Gerhart, Jacqueline L.</au><au>Feldstein, Leora R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccine Effectiveness against Mpox in the United States</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2023-10-12</date><risdate>2023</risdate><volume>389</volume><issue>15</issue><spage>1440</spage><epage>1441</epage><pages>1440-1441</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Deputy et al. (June 29 issue)
1
report the estimated vaccine effectiveness of JYNNEOS vaccination against mpox in a case–control study. Their estimate of vaccine effectiveness with a single dose is substantially lower than the estimates from previous reports. The definition of the control group (patients with an incident diagnosis of human immunodeficiency virus [HIV] infection or a new or refill order for preexposure prophylaxis against HIV infection) may not be representative of the patients who are intended to receive the vaccine against mpox. Indeed, only 309 of 2266 patients with mpox (13.6%) met these criteria. Moreover, the . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>37819966</pmid><doi>10.1056/NEJMc2309583</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2023-10, Vol.389 (15), p.1440-1441 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2876636898 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Conflicts of interest Disease control Disease prevention Effectiveness studies Estimates HIV Human immunodeficiency virus Humans Immunization Infections Mpox Mpox (monkeypox) Prophylaxis United States Vaccine Efficacy Vaccines |
| title | Vaccine Effectiveness against Mpox in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A45%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccine%20Effectiveness%20against%20Mpox%20in%20the%20United%20States&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Arbel,%20Ronen&rft.date=2023-10-12&rft.volume=389&rft.issue=15&rft.spage=1440&rft.epage=1441&rft.pages=1440-1441&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc2309583&rft_dat=%3Cproquest_cross%3E2876058167%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2876058167&rft_id=info:pmid/37819966&rfr_iscdi=true |